Bristol-Myers Squibb Company beats revenue forecasts & raises 2025 guidance. Click for key BMY catalysts, risks, and outlook ...

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Q2 2025 Earnings Call Transcript July 31, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is $1.46, expectations were $1.07. Operator: Good day, and welcome to the ...

Myers Squibb (BMY) is a contrarian value play with a 5.39% dividend yield, strong growth strategy, and long-term potential.

Trump demanded that pharmaceutical companies lower their drug prices. But it's unclear how the government may enforce the ...

Bristol Myers Squibb tested Cobenfy as an adjunctive treatment with atypical antipsychotics for schizophrenia in the Phase ...

Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

Bristol Myers Squibb (NYSE: BMY) has posted better-than-expected second-quarter 2025 results, driven by strong sales of its ...

Bristol Myers Squibb surpassed analyst expectations with a strong Q2, as notable brands Eliquis, Opdivo, and Revlimid drove ...